NEW YORK (GenomeWeb) – Cellecta has acquired a non-exclusive, worldwide license to ERS Genomics’ CRISPR-Cas9 intellectual property for use with its research tools and services, the companies announced today.
Specific terms of the deal were not disclosed.
ERS was founded to provide broad access to the IP, which is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden. The firm has signed licensing deals with a number of firms including Taconic Biosciences, Horizon Discovery, and DuPont Pioneer.
“CRISPR-Cas9 technology is proving to be an increasingly valuable tool for target discovery and validation applications,” Cellecta COO Paul Diehl said in a statement. “Cellecta is pleased to offer a growing portfolio of products and services to aid researchers in obtaining a deeper understanding of gene function using this important technology.”